1. Home
  2. CRDF vs HRTX Comparison

CRDF vs HRTX Comparison

Compare CRDF & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • HRTX
  • Stock Information
  • Founded
  • CRDF 1999
  • HRTX 1983
  • Country
  • CRDF United States
  • HRTX United States
  • Employees
  • CRDF N/A
  • HRTX N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • HRTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRDF Health Care
  • HRTX Health Care
  • Exchange
  • CRDF Nasdaq
  • HRTX Nasdaq
  • Market Cap
  • CRDF 233.5M
  • HRTX 276.1M
  • IPO Year
  • CRDF N/A
  • HRTX 1987
  • Fundamental
  • Price
  • CRDF $2.32
  • HRTX $1.40
  • Analyst Decision
  • CRDF Strong Buy
  • HRTX Strong Buy
  • Analyst Count
  • CRDF 6
  • HRTX 2
  • Target Price
  • CRDF $10.58
  • HRTX $4.50
  • AVG Volume (30 Days)
  • CRDF 2.9M
  • HRTX 2.4M
  • Earning Date
  • CRDF 07-29-2025
  • HRTX 08-08-2025
  • Dividend Yield
  • CRDF N/A
  • HRTX N/A
  • EPS Growth
  • CRDF N/A
  • HRTX N/A
  • EPS
  • CRDF N/A
  • HRTX N/A
  • Revenue
  • CRDF $545,000.00
  • HRTX $149,694,000.00
  • Revenue This Year
  • CRDF N/A
  • HRTX $12.08
  • Revenue Next Year
  • CRDF N/A
  • HRTX $12.57
  • P/E Ratio
  • CRDF N/A
  • HRTX N/A
  • Revenue Growth
  • CRDF N/A
  • HRTX 9.78
  • 52 Week Low
  • CRDF $2.09
  • HRTX $1.04
  • 52 Week High
  • CRDF $5.64
  • HRTX $2.68
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 34.12
  • HRTX 37.01
  • Support Level
  • CRDF $2.22
  • HRTX $1.25
  • Resistance Level
  • CRDF $2.56
  • HRTX $1.47
  • Average True Range (ATR)
  • CRDF 0.13
  • HRTX 0.10
  • MACD
  • CRDF 0.01
  • HRTX -0.00
  • Stochastic Oscillator
  • CRDF 25.64
  • HRTX 30.43

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Share on Social Networks: